AbbVie Inc
ABBV186.960USD
-14.790-7.33%
收盤 04/04, 16:00（美東）報價延遲15分鐘
330.03B總市值
77.87本益比TTM
關於 AbbVie Inc 公司
AbbVie Inc. 是一家全球性、多元化、以研究爲基礎的生物製藥公司。該公司研究和開發、製造、商業化和銷售藥物和療法。其產品組合包括免疫學、腫瘤學、美學、神經科學、眼部護理和其他專業。免疫學包括風溼病學、皮膚病學和胃腸病學。腫瘤學包括急性髓細胞白血病、急性淋巴細胞白血病、慢性淋巴細胞白血病和瀰漫性大 B 細胞淋巴瘤。神經科學包括帕金森病、偏頭痛、運動障礙、精神障礙和阿爾茨海默病。眼部護理包括慢性乾眼症、青光眼、老年性視網膜疾病和屈光不正。美學包括 Botox Cosmetic、The Juvederm Collection of Fillers 等。其 NX-13 用於治療潰瘍性結腸炎和克羅恩病。其CEL383用於治療炎症性腸病。其ALIA-1758用於治療阿爾茨海默病患者。
公司簡介
公司代碼ABBV
公司名稱AbbVie Inc
上市日期Jan 02, 2013
成立日期2012
CEOMr. Robert A. Michael, CPA
員工數量55000
證券類型Ordinary Share
年結日Jan 02
公司地址1 N Waukegan Rd
城市NORTH CHICAGO
上市交易所NYSE Consolidated
國家United States of America
郵編60064
電話18479327900
網址https://www.abbvie.com/
公司代碼ABBV
上市日期Jan 02, 2013
成立日期2012
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Richard A. Gonzalez
Mr. Richard A. Gonzalez
Executive Chairman of the Board
Executive Chairman of the Board
386.48K
-2.18%
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
183.77K
-17.22%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
133.43K
--
Mr. Glenn Fletcher Tilton
Mr. Glenn Fletcher Tilton
Independent Director
Independent Director
50.71K
--
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
42.28K
+16.15%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
41.74K
--
Ms. Roxanne S. Austin, CPA
Ms. Roxanne S. Austin, CPA
Lead Independent Director
Lead Independent Director
37.26K
--
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
34.44K
--
Mr. Frederick H. (Rick) Waddell
Mr. Frederick H. (Rick) Waddell
Independent Director
Independent Director
27.75K
--
Ms. Melody B. Meyer
Ms. Melody B. Meyer
Independent Director
Independent Director
15.29K
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Richard A. Gonzalez
Mr. Richard A. Gonzalez
Executive Chairman of the Board
Executive Chairman of the Board
386.48K
-2.18%
Dr. Azita Saleki-Gerhardt, Ph.D.
Dr. Azita Saleki-Gerhardt, Ph.D.
Executive Vice President, Chief Operations Officer
Executive Vice President, Chief Operations Officer
183.77K
-17.22%
Mr. Thomas C. (Tom) Freyman, CPA
Mr. Thomas C. (Tom) Freyman, CPA
Independent Director
Independent Director
133.43K
--
Mr. Glenn Fletcher Tilton
Mr. Glenn Fletcher Tilton
Independent Director
Independent Director
50.71K
--
Dr. Roopal Thakkar, M.D.
Dr. Roopal Thakkar, M.D.
Executive Vice President - Research & Development, Chief Scientific Officer
Executive Vice President - Research & Development, Chief Scientific Officer
42.28K
+16.15%
Mr. Edward J. (Ed) Rapp
Mr. Edward J. (Ed) Rapp
Independent Director
Independent Director
41.74K
--
收入明細
單位: USD更新時間: 4月2日 週三
單位: USD更新時間: 4月2日 週三
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Immunology-SKYRIZI
11.72B
20.80%
Immunology-HUMIRA
8.99B
15.96%
Immunology-RINVOQ
5.97B
10.60%
Hematologic Oncology-IMBRUVICA
3.35B
5.94%
Neuroscience-Botox Therapeutic
3.28B
5.83%
Other
23.02B
40.87%
地區USD
名稱
營收
佔比
United States
40.78B
72.39%
International
11.51B
20.42%
All other countries
3.03B
5.38%
Germany
1.47B
2.60%
Japan
1.12B
1.99%
Other
-1.57B
-2.79%
業務
地區
業務USD
名稱
營收
佔比
Immunology-SKYRIZI
11.72B
20.80%
Immunology-HUMIRA
8.99B
15.96%
Immunology-RINVOQ
5.97B
10.60%
Hematologic Oncology-IMBRUVICA
3.35B
5.94%
Neuroscience-Botox Therapeutic
3.28B
5.83%
Other
23.02B
40.87%
股東統計
更新時間: 2月21日 週五
更新時間: 2月21日 週五
持股股東
股東類型
持股股東
股東統計
佔比
The Vanguard Group, Inc.
9.74%
BlackRock Institutional Trust Company, N.A.
5.09%
State Street Global Advisors (US)
4.50%
Geode Capital Management, L.L.C.
2.10%
Capital Research Global Investors
1.92%
Other
76.65%
持股股東
股東統計
佔比
The Vanguard Group, Inc.
9.74%
BlackRock Institutional Trust Company, N.A.
5.09%
State Street Global Advisors (US)
4.50%
Geode Capital Management, L.L.C.
2.10%
Capital Research Global Investors
1.92%
Other
76.65%
股東類型
股東統計
佔比
Investment Advisor
33.85%
Investment Advisor/Hedge Fund
29.79%
Research Firm
2.90%
Bank and Trust
2.23%
Pension Fund
2.22%
Sovereign Wealth Fund
1.52%
Insurance Company
0.63%
Hedge Fund
0.51%
Foundation
0.12%
Other
26.23%
機構持股
更新時間: 2月20日 週四
更新時間: 2月20日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
5158
1.32B
74.38%
+12.54M
2024Q4
5219
1.31B
74.47%
+8.91M
2024Q3
4974
1.30B
73.54%
-7.44M
2024Q2
4916
1.30B
73.53%
+2.27M
2024Q1
4930
1.29B
72.58%
-1.47M
2023Q4
4882
1.28B
72.31%
-1.48M
2023Q3
4694
1.27B
71.87%
-12.06M
2023Q2
4688
1.26B
71.51%
-30.42M
2023Q1
4658
1.27B
71.97%
-18.58M
2022Q4
4628
1.27B
71.69%
-10.55M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
172.31M
9.74%
+1.45M
+0.85%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
90.08M
5.09%
+893.98K
+1.00%
Dec 31, 2024
State Street Global Advisors (US)
79.62M
4.5%
+553.55K
+0.70%
Dec 31, 2024
Geode Capital Management, L.L.C.
37.14M
2.1%
+983.89K
+2.72%
Dec 31, 2024
Capital Research Global Investors
33.98M
1.92%
+778.13K
+2.34%
Dec 31, 2024
JP Morgan Asset Management
33.90M
1.92%
+881.83K
+2.67%
Dec 31, 2024
Capital International Investors
28.53M
1.61%
-8.25M
-22.44%
Dec 31, 2024
Charles Schwab Investment Management, Inc.
27.44M
1.55%
+3.60M
+15.10%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
25.10M
1.42%
+2.62M
+11.64%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
22.68M
1.28%
+844.34K
+3.87%
Dec 31, 2024
查看更多
持股ETF
更新時間: 4月2日 週三
更新時間: 4月2日 週三
機構名稱
佔比
First Trust Morningstar Dividend Leaders Index Fund
9.82%
First Trust NASDAQ Pharmaceuticals ETF
8.98%
VanEck Pharmaceutical ETF
7.38%
Proshares Ultra Health Care
6.8%
Health Care Select Sector SPDR Fund
6.8%
iShares U.S. Healthcare ETF
6.61%
Goldman Sachs Future Health Care Equity ETF
6.07%
Fidelity MSCI Health Care Index ETF
5.92%
Invesco Pharmaceuticals ETF
5.84%
Themes US Cash Flow Champions ETF
5.7%
查看更多
First Trust Morningstar Dividend Leaders Index Fund
佔比9.82%
First Trust NASDAQ Pharmaceuticals ETF
佔比8.98%
VanEck Pharmaceutical ETF
佔比7.38%
Proshares Ultra Health Care
佔比6.8%
Health Care Select Sector SPDR Fund
佔比6.8%
iShares U.S. Healthcare ETF
佔比6.61%
Goldman Sachs Future Health Care Equity ETF
佔比6.07%
Fidelity MSCI Health Care Index ETF
佔比5.92%
Invesco Pharmaceuticals ETF
佔比5.84%
Themes US Cash Flow Champions ETF
佔比5.7%
分紅派息
近5年累計派現
48.58B
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Oct 30, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 06, 2024
ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 21, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 15, 2024
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option
Apr 15, 2024
May 15, 2024
Apr 12, 2024
Oct 27, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option
Jan 16, 2024
Feb 15, 2024
Jan 12, 2024
Sep 11, 2023
ABBV.NB Final Cash Dividend of gross USD 1.48 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option
Oct 13, 2023
Nov 15, 2023
Oct 12, 2023
Jun 22, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option
Jul 14, 2023
Aug 15, 2023
Jul 13, 2023
Feb 16, 2023
ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option
Apr 14, 2023
May 15, 2023
Apr 13, 2023
Oct 28, 2022
ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option
Jan 13, 2023
Feb 15, 2023
Jan 12, 2023
Sep 09, 2022
ABBV.NB Final Cash Dividend of gross USD 1.41 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option
Oct 14, 2022
Nov 15, 2022
Oct 13, 2022
查看更多
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據